Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
주식 순위 #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
주가
$0.25974701
마지막 동기화: 2025-01-06
시가총액
$2.04M
변동 (1일)
0.74%
변동 (1년)
0.00%
국가
FR
거래 Acticor Biotech SAS (ALACT)

카테고리

Acticor Biotech SAS (ALACT)의 P/S 비율
September 2026 기준 P/S 비율 TTM: 0.00
Acticor Biotech SAS의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0.00입니다. 2022년 말 기준 P/S 비율은 0.00였습니다.
Acticor Biotech SAS의 P/S 비율 기록 (2010 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 432.73 16,252.85%
2017 2.65 56.77%
2016 1.69 23.03%
2015 1.37 16.08%
2014 1.18 -11.28%
2013 1.33 -13.75%
2012 1.54 -29.62%
2011 2.19 -58.15%
2010 5.24 0.00%
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
10.44 -
US
12.01 -
NL
3.76 -
AU
26.12 -
US
- -
CH